Jim Cramer says insurance companies will pay for ‘revolutionary’ weight-loss drugs for their members
CNBC’s Jim Cramer on Monday emphasized his belief that GLP-1 drugs primarily used to treat diabetes and obesity and the companies that make them, like Eli Lilly and Novo Nordisk, will be very valuable.
“At the end of the day, the use cases are tested. And for millions of people, it’ll be cheaper for the insurance companies to shell out for the new weight-loss drugs than to let their morbidly obese members just get heart disease,” he said. $Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
The content is carried from Twitter "Inverse Cramer ETF‘’.
1081Followers
31Following
3392Visitors
Follow